|Bid||3.8400 x 3200|
|Ask||3.9000 x 3100|
|Day's Range||3.6200 - 4.1400|
|52 Week Range||0.0500 - 7.4500|
|Beta (5Y Monthly)||-5.45|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 10, 2020 - Aug 14, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Shares of companies with COVID-19 vaccine candidates were mixed in volatile trading Monday, after the promising results from trials of vaccine candidates from Pfizer Inc. and BioNTech SE and AstraZeneca PLC. Shares of iBio Inc. , which is working with Beijing CC-Pharming Ltd. on a plant-based vaccine to treat the coronavirus, soared 43% in morning trading on volume of 45.5 million shares, which is already nearly double the full-day average. Inovio Pharmaceuticals Inc. , which announced last month that the Department of Defense will pay $71 million to fund the manufacturing of a device used to administer Inovio vaccines, saw its stock drop 7.9%. Among other companies with vaccine candidates, shares of Moderna Inc. sank 12% in active trading after a J.P. Morgan downgrade on valuation concerns, Novavax Inc. shed 5%, Vaxart Inc. gained 1.9%. Meanwhile, shares of AstraZeneca fell 2.9%, Pfizer gained 1.8% and BioNTech advanced 4.9%. The S&P 500 was up less than 0.1% in morning trading.
The last piece of news from iBio (NYSEMKT:IBIO) was the June 26 press release letting investors know that IBIO stock had been added to the Russell 2000 and Russell 3000 indexes as part of FTSE Russell's annual reconstitution process. Source: Shutterstock The company's shareholders are undoubtedly hoping that its addition to the Russell 1000 isn't too far away. However, for now, this will have to do. Who's Betting on IBIO StockIn my last article about the company in late May, I wrote about the relationship between iBio and Lincoln Park Capital, a Chicago-based investment firm. To this day, I know very little about the organization. And frankly, given all the speculation driving biotechs these days, I don't care to know.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * The 7 Best Stocks to Invest in Right Now As my late father-in-law used to say when my wife and I first started dating: "I've seen so many come, and so many go, I'm not going to bother learning his name until I know he's sticking around."That man had some fantastic one-liners; I miss him immensely. But I digress. The reason I mentioned iBio's addition to the indexes is that it shows how little investors know about what's happening behind the scenes at iBio's vaccine central. There's a shortage of information available. Navellier Likes Its ChancesSure, my InvestorPlace colleague, Louis Navellier, had a bunch to say recently about the company's lichenase booster molecule, or LicKM for short. It could be the pathway to a single-dose novel coronavirus vaccine. At this point of the conversation, you offer to sell me Florida swampland, because if I'm buying iBio based on something sounding weirdly similar to Lik-M-Aid, the candy I devoured as a kid, I deserve to be taken to the cleaners.Navellier's been writing about stocks a lot longer than I have, so I'm confident he's done his homework. However, I'm also convinced that I have no possible way of confirming whether this is a home run or foul ball behind home plate. A margin of safety is always in the back of my mind. If you told me that I could only invest in one vaccine candidate's stock, iBio would not be it. Probably not even in the top five. But, I'm also willing to admit that my understanding of biotechnology is only slightly better than my comfort discussing quantum physics. All I really know about Moderna (NASDAQ:MRNA) is that its executives are making out like bandits -- CEO Stephane Bancel has sold over $21 million since January and Tal Zaks, its chief medical officer, has sold more, netting $35 million in 2020 -- but beyond that, the company, like iBio, is in a race against time. Maybe it wins, maybe it doesn't.It sounds a lot like Vegas to me. One thing I did mention in my last article about iBio is that unless you're a speculator, you've got safer options."[A]s I said in March, unless you know a lot about health care, you're wiser to put any bet you make on something like Pfizer (NYSE:PFE) or Johnson & Johnson (NYSE:JNJ), whose entire future isn't tied up in the vaccine's success or failure," I wrote May 27. A Safer OptionNothing's changed in that regard, which is why I believe you might want to consider investing in the ETFMG Treatments Testing and Advancements ETF (NYSEARCA:GERM), a fund that tracks the performance of the Prime Treatments, Testing and Advancements Index, a passive index of U-S.-listed companies involved in R&D, vaccines, therapies and testing technologies. The ETF itself only launched in mid-June. It's from the same people who brought investors the ETFMG Alternative Harvest ETF (NYSEARCA:MJ), a fund focused on the cannabis industry. At 0.68%, GERM's management expense ratio isn't cheap, but it gets the job done, which is to lay down a bet on Covid-19. The fund's top three holdings are Novavax (NASDAQ:NVAX), Alnylam Pharmaceuticals (NASDAQ:ALNY), and Moderna, weighted at 6.95%, 5.85%, and 4.95%, respectively. Ibio's farther down the 56 holdings with a weighting of just 0.40%. However, by eliminating the company-specific risk, you give yourself a much better chance of benefiting from a vaccine solution.But, as I said earlier, I'm never going to be confused with Dr. Fauci. Will Ashworth has written about investments full-time since 2008. Publications where he's appeared include InvestorPlace, The Motley Fool Canada, Investopedia, Kiplinger, and several others in both the U.S. and Canada. He particularly enjoys creating model portfolios that stand the test of time. He lives in Halifax, Nova Scotia. At the time of this writing Will Ashworth did not hold a position in any of the aforementioned securities. More From InvestorPlace * Why Everyone Is Investing in 5G All WRONG * America's 1 Stock Picker Reveals His Next 1,000% Winner * Revolutionary Tech Behind 5G Rollout Is Being Pioneered By This 1 Company * Radical New Battery Could Dismantle Oil Markets The post A Safer Way to Play IBio Stock Could Spread Like the CoronavirusÂ appeared first on InvestorPlace.
Stuck in a "soft" quarantine, I turned to what most people did during the hard quarantine - watch the film Contagion. It's been quite a while since I last saw the terrifying depiction of a devastating pandemic. After giving it another run through, I'm struck at how ominously accurate the movie is regarding the novel coronavirus. And this brings me to iBio (NYSEAMERICAN:IBIO) and specifically, IBIO stock.Source: Shutterstock Over the last few months that I covered this biotechnology firm, I described its equity as a speculative opportunity to advantage with "dumb" money. In other words, as a pure gamble, you could do a lot worse. Should the organization live up to its claim of mass-production of a coronavirus vaccine, IBIO stock could veritably skyrocket.But as shares have steadily ticked higher since early April and as demand for a vaccine consistently rises, I'm willing to sharpen my prognostication for iBio. Rather than it being a dumb money move, it's a rational one.InvestorPlace - Stock Market News, Stock Advice & Trading TipsDon't get me wrong - IBIO stock is still ultra-risky. However, what has given me more confidence in the underlying company is that a return to normalcy may be impossible without a biological solution to this crisis.In carefully watching Contagion, I realized what made this narrative so compelling from a filmmaking perspective is plot organization. Starting with the initial strike, the protagonists work through the fictional MEV-1 virus' second wave, which then culminates in a vaccine and its unwieldy distribution. * The 7 Best Stocks to Invest in Right Now Each segment in the film features its own conflict. What intrigued me about Contagion's final act was that the mere production of a vaccine wasn't enough. This brings me to my first of three bullish factors for iBio. Scale Is the Distinguisher for IBIO StockAs the New York Times spelled out a few months ago, several entities are developing a novel coronavirus vaccine. Contrary to some people's opinions, this development process is long, arduous and expensive. It's not as easy as injecting disinfectants.Therefore, you're looking at a two-front battle. First, a pharmaceutical company must forward a truly viable and effective vaccine. Second, it's got to bring that vaccine to scale so that the entire nation can benefit. Both challenges will be difficult to overcome.But as I pointed out in early June, scale is what distinguishes IBIO stock from the competition. I wrote:The driving force behind the company is a proprietary technology called the FastPharming Manufacturing System. Using a relative to the tobacco plant as a "bioreactor," iBio can theoretically take a vaccine and scale it up to necessary commercial volume. According to iBio co-chairman and CEO Tom Isett, the firm can "make about 500 million doses of high-quality product annually."Granted, the company must live up to its claims. Otherwise, it can go downhill quickly for IBIO stock. Nevertheless, if it can achieve this scale, the U.S. government's ambitious target to get a vaccine within a 12- to 18-month window is much more credible. Multiple Paths to SuccessAnother previously not well known pharmaceutical company in the coronavirus vaccine race is Inovio Pharmaceuticals (NASDAQ:INO). Despite question marks over its candidate's viability, INO shares are still performing outstandingly. In part, this may be because there are multiple paths to success.According to Dr. James Samuel, a regents' professor and the head of the Department of Microbial Pathogenesis and Immunology at the Texas A&M University College of Medicine, initial coronavirus vaccines may be helpful for healthy individuals. However, Dr. Samuel cautioned that other vaccines may need to be developed for medically vulnerable individuals.As Dr. Samuel put it, "The challenge is a lot more complicated than a single vaccine… The scale of the problem alone is unprecedented. This will not be a horse race with a single winner."Therefore, just because a company beats everyone else to an effective vaccine doesn't spell disaster for others. First, scaling up that vaccine is a challenge, but one that would better suit iBio. Second, multiple vaccines may be necessary to fully address the Covid-19 pandemic.So, IBIO stock may have a safety margin that some investors may not be aware of. Economic Demand Is SurgingWhoever forwards genuine solutions, investors of that organization will find themselves loving life (assuming they don't get Covid-19 and die). But the financial implications of a vaccine don't just end on Wall Street. Indeed, the domestic and perhaps the international economy is dependent on it.For the most part, Americans have graciously adopted previously foreign practices, such as wearing masks and practicing social distancing. But skyrocketing new daily coronavirus cases, along with an uptick in Covid-19-related deaths have cast a shadow on these measures' efficacy.If only from the power of perception, the U.S. desperately needs a vaccine. It's much easier to convince businesses to reopen and people to spend if we have a substantive, meaningful solution.This also means that there's extra leeway in terms of the vaccine development process. Stated differently, a less-than-desirable result may not spell immediate red ink for pharmaceutical players. And that adds another measure of confidence toward IBIO stock.A former senior business analyst for Sony Electronics, Josh Enomoto has helped broker major contracts with Fortune Global 500 companies. Over the past several years, he has delivered unique, critical insights for the investment markets, as well as various other industries including legal, construction management, and healthcare. As of this writing, he did not hold a position in any of the aforementioned securities. More From InvestorPlace * Why Everyone Is Investing in 5G All WRONG * America's 1 Stock Picker Reveals His Next 1,000% Winner * Revolutionary Tech Behind 5G Rollout Is Being Pioneered By This 1 Company * Radical New Battery Could Dismantle Oil Markets The post 3 Reasons to Invest in, Not Trade iBio appeared first on InvestorPlace.